Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Adocia (ADOC) EUR0.10

Sell:€9.55 Buy:€9.84 Change: €0.09 (0.94%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: €0.09 (0.94%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: €0.09 (0.94%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

Contact details

115 avenue Lacassagne
+33 (4) 72610610

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€67.55 million
Shares in issue:
6.99 million
Euronext Paris

Key personnel

  • Gerard Soula
    Chairman of the Board, Chief Executive Officer
  • Olivier Soula
    Deputy Chief Executive Officer, Vice President - Research & Development, Director
  • Valerie Danaguezian
    Chief Financial Officer, Administrative Director
  • You-Ping Chan
    Scientific Director
  • Remi Soula
    Business Development and Intellectual Property Director
  • Geraldine Soula
    Director of Development and Human Resources
  • Bertrand Alluis
    Head of Analysis Department and Project Manager
  • Richard Charvet
    Head of Chemistry Department
  • Jose Correia
    Head of the Preclinical and Clinical Department, HSQE Manager and Project Manager
  • David Duracher
    Head of Pharmaceutical Development and Physical Chemistry Departments

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.